Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2026-05-28 Major Shareholding Noti…
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 91% confidence The document is a regulatory disclosure published by Finansinspektionen detailing a change in significant shareholding (crossing a 5% threshold) for Isofol Medical AB, including before/after share counts and voting rights. This matches the definition of a Major Shareholding Notification (code MRQ).
2026-05-28 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a notification of a shareholding crossing a 5% threshold filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details the before and after shareholding percentages, voting rights, date, and legal basis under FITA. This matches the definition of a Major Shareholding Notification (MRQ).
2026-05-26 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a regulatory disclosure of a change in significant share ownership levels filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details the holdings before and after a transaction, thresholds for share and vote limits, and cites legal requirements for major shareholding notifications. This matches the definition for Major Shareholding Notification (MRQ).
2026-05-22 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 92% confidence The document is a regulatory announcement from the Swedish Financial Supervisory Authority (Finansinspektionen) disclosing a major shareholding notification: Avanza Bank Holding AB’s acquisition of a 5.00339% stake in Isofol Medical AB. It reports the crossing of the 5% threshold with detailed holdings before and after the transaction. This precisely matches the “Major Shareholding Notification” category.
2026-05-21 English
Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a press bulletin from Isofol Medical’s Annual General Meeting held on May 19, 2026, summarizing the resolutions passed by shareholders (e.g., adoption of financial statements, election of board members, remuneration guidelines, warrant programs, authorization to issue new shares). It does not include presentation materials or detailed financial statements, but rather the official voting outcomes and resolutions adopted. This matches the definition of a ‘Declaration of Voting Results & Voting Rights Announcement’ (DVA).
2026-05-19 English
Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release summarizing the outcomes of Isofol Medical AB’s Annual General Meeting held on May 19, 2026. It details shareholder votes on approval of financial statements, discharge of board and CEO, dividend policy, board and auditor elections, director fees, adoption of remuneration guidelines, approval of option programs, and board authorizations. This is a classic announcement of voting results at an AGM rather than the full reports or regulatory filing itself. Therefore, it should be classified as a Declaration of Voting Results (DVA).
2026-05-19 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.